Gsa Capital Partners LLP Cardiff Oncology, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 380,070 shares of CRDF stock, worth $1.39 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
380,070
Previous 186,650
103.63%
Holding current value
$1.39 Million
Previous $498,000
231.33%
% of portfolio
0.12%
Previous 0.04%
Shares
13 transactions
Others Institutions Holding CRDF
# of Institutions
125Shares Held
25.3MCall Options Held
866KPut Options Held
203K-
Commodore Capital LP New York, NY5.38MShares$19.8 Million2.34% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$9.65 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$8.39 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.54MShares$5.65 Million0.18% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$5.29 Million3.38% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $159M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...